Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)
In Thousands, unless otherwise specified
 9 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Cash flows from operating activities:    
Net loss $ (2,363) $ (3,115)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock compensation expense 272 507
Fair value adjustment of common stock warrants (10) (3)
Depreciation 24 10
Loss on disposal of property and equipment 0 17
Amortization of intangible assets 156 82
Accrued interest on note receivable (25) (25)
Deferred tax liability (61) (52)
Accrued interest promissory note 4 0
Changes in operating assets and liabilities:    
Accounts receivable 195 0
Prepaid expenses and other assets (62) (93)
Deferred financing costs (129) 0
Accounts payable, accrued expenses and other liabilities 200 (338)
Current assets and liabilities from discontinued operations, net 143 177
Net cash used in operating activities (1,656) (2,833)
Cash flows from investing activities:    
Acquisition of property and equipment (17) (90)
Cash received from acquisition 0 476
Issuance of note receivable 0 (300)
Net cash (used in)/provided by investing activities (17) 86
Net decrease in cash and cash equivalents (1,673) (2,747)
Cash and cash equivalents at beginning of period 4,039 [1] 7,820
Cash and cash equivalents at end of period 2,366 5,073
Supplemental disclosure of non-cash activities:    
Shares issued in CollabRx acquisition 0 932
Note receivable used as consideration for CollabRx acquisition 0 300
Promissory note issued in CollabRx acquisition 0 500
Fair value of assets acquired in CollabRx acquisition 0 2,253
Liabilities assumed in CollabRx acquisition $ 0 $ 997
[1] Derived from the Company's audited consolidated financial statements.